triamterene Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2728 396-01-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • triamterene
  • diurene
  • pterofen
  • pterophene
  • triamteren
  • triamteril
  • triteren
A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.
  • Molecular weight: 253.27
  • Formula: C12H11N7
  • CLOGP: 1.61
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 129.62
  • ALOGS: -2.42
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.03 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.15 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 51 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 13 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 63 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.42 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 10, 1964 FDA CONCORDIA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coronary artery disease 74.72 11.05 103 31631 33649 46620679
Myocardial infarction 52.82 11.05 166 31568 97362 46556966
Exposure during pregnancy 52.59 11.05 6 31728 108206 46546122
Off label use 52.15 11.05 113 31621 379728 46274600
Crystal nephropathy 48.50 11.05 19 31715 806 46653522
Oedema peripheral 44.15 11.05 220 31514 159486 46494842
Cerebrovascular accident 41.61 11.05 157 31577 100882 46553446
Blood potassium decreased 39.67 11.05 83 31651 37980 46616348
Rheumatoid arthritis 35.86 11.05 68 31666 240147 46414181
Osteoarthritis 33.95 11.05 106 31628 61919 46592409
Acquired haemophilia 33.12 11.05 15 31719 916 46653412
Drug ineffective 32.01 11.05 301 31433 677537 45976791
Gastrooesophageal reflux disease 31.83 11.05 117 31617 74227 46580101
Hyperlipidaemia 31.53 11.05 50 31684 18489 46635839
Synovitis 30.66 11.05 3 31731 61072 46593256
Transient ischaemic attack 30.59 11.05 71 31663 34832 46619496
Hyponatraemic encephalopathy 30.57 11.05 10 31724 249 46654079
Mitral valve incompetence 29.56 11.05 49 31685 18803 46635525
Cardiac failure congestive 29.41 11.05 132 31602 91618 46562710
Intentional overdose 28.28 11.05 5 31729 64939 46589389
Ventricular hypertrophy 27.64 11.05 22 31712 3792 46650536
Lower respiratory tract infection 26.89 11.05 3 31731 55086 46599242
Product complaint 26.88 11.05 37 31697 12064 46642264
Drug intolerance 26.25 11.05 37 31697 147012 46507316
Depression 25.33 11.05 200 31534 169904 46484424
Angina unstable 24.65 11.05 28 31706 7520 46646808
C-reactive protein increased 24.47 11.05 5 31729 58585 46595743
Hypokalaemia 24.11 11.05 121 31613 87903 46566425
Tricuspid valve incompetence 23.33 11.05 37 31697 13680 46640648
Lacunar infarction 22.93 11.05 19 31715 3466 46650862
Dizziness 22.04 11.05 339 31395 340075 46314253
Pyrexia 21.93 11.05 143 31591 348659 46305669
Injury 21.17 11.05 72 31662 43955 46610373
Blood pressure increased 21.14 11.05 153 31581 126513 46527815
Hypertension 21.08 11.05 215 31519 196141 46458187
Blood pressure inadequately controlled 20.98 11.05 20 31714 4386 46649942
Neutropenia 20.94 11.05 41 31693 143163 46511165
Ventricular tachycardia 20.06 11.05 39 31695 16928 46637400
Deep vein thrombosis 20.00 11.05 107 31627 79666 46574662
Febrile neutropenia 19.84 11.05 21 31713 94606 46559722
Abortion spontaneous 19.80 11.05 3 31731 43643 46610685
Angina pectoris 19.77 11.05 51 31683 26724 46627604
Anxiety 19.41 11.05 199 31535 181758 46472570
Focal segmental glomerulosclerosis 19.20 11.05 12 31722 1409 46652919
Product use issue 18.75 11.05 22 31712 94622 46559706
Hyponatraemia 18.42 11.05 125 31609 101207 46553121
Spinal stenosis 17.55 11.05 31 31703 12512 46641816
Blood cholesterol increased 17.14 11.05 63 31671 39950 46614378
Carpal tunnel syndrome 17.01 11.05 35 31699 15824 46638504
Overdose 16.89 11.05 27 31707 101952 46552376
Product use in unapproved indication 16.82 11.05 22 31712 90251 46564077
Chest pain 16.56 11.05 188 31546 176136 46478192
Emotional distress 16.35 11.05 52 31682 30655 46623673
General physical health deterioration 16.19 11.05 34 31700 115735 46538593
Myocardial ischaemia 15.93 11.05 30 31704 12719 46641609
Feeling abnormal 15.92 11.05 142 31592 124918 46529410
Intentional product use issue 15.88 11.05 8 31726 52772 46601556
Toxicity to various agents 15.86 11.05 82 31652 211684 46442644
Transient acantholytic dermatosis 15.61 11.05 4 31730 40 46654288
Suicide attempt 15.60 11.05 9 31725 55027 46599301
Blood triglycerides increased 15.06 11.05 28 31706 11755 46642573
Hand deformity 14.33 11.05 3 31731 34571 46619757
Hepatic function abnormal 14.24 11.05 3 31731 34418 46619910
Borderline glaucoma 14.06 11.05 3 31731 12 46654316
Diabetic neuropathy 14.01 11.05 15 31719 3774 46650554
Infusion related reaction 13.92 11.05 30 31704 101178 46553150
Diverticulum 13.54 11.05 26 31708 11180 46643148
Asthenia 13.48 11.05 291 31443 310784 46343544
Atrial fibrillation 13.37 11.05 118 31616 103472 46550856
Death 13.29 11.05 155 31579 335393 46318935
Thrombocytopenia 13.24 11.05 43 31691 126538 46527790
Pulmonary embolism 13.16 11.05 122 31612 108463 46545865
Systemic lupus erythematosus 13.07 11.05 15 31719 65165 46589163
Aortic valve incompetence 12.88 11.05 18 31716 5952 46648376
Hypertensive heart disease 12.84 11.05 12 31722 2566 46651762
Vitamin B6 deficiency 12.53 11.05 4 31730 92 46654236
Lung neoplasm 11.93 11.05 17 31717 5723 46648605
Carotid artery stenosis 11.89 11.05 16 31718 5104 46649224
Hiatus hernia 11.64 11.05 33 31701 18269 46636059
Muscle spasms 11.43 11.05 131 31603 122982 46531346
Back pain 11.28 11.05 203 31531 209836 46444492
Skin discolouration 11.21 11.05 48 31686 32632 46621696
Haemorrhoids 11.12 11.05 33 31701 18744 46635584
Fear 11.12 11.05 30 31704 16142 46638186
Arteriosclerosis 11.05 11.05 22 31712 9711 46644617

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coronary artery disease 52.66 14.01 73 9792 49639 29892974
Myocardial infarction 44.21 14.01 115 9750 125510 29817103
Cerebrovascular accident 42.06 14.01 88 9777 83389 29859224
Dizziness 27.59 14.01 132 9733 194777 29747836
Cardiac failure congestive 21.61 14.01 69 9796 84338 29858275
Bundle branch block left 19.26 14.01 15 9850 5189 29937424
Off label use 19.15 14.01 33 9832 249257 29693356
Emotional distress 17.95 14.01 24 9841 15741 29926872
Lymphopenia 16.48 14.01 21 9844 13142 29929471
Mitral valve incompetence 16.39 14.01 21 9844 13213 29929400
Arteriosclerosis coronary artery 15.88 14.01 19 9846 11157 29931456
Activated partial thromboplastin time prolonged 15.80 14.01 16 9849 7812 29934801
Chest pain 14.71 14.01 77 9788 117550 29825063
Electrocardiogram U wave present 14.59 14.01 3 9862 23 29942590

Pharmacologic Action:

SourceCodeDescription
ATC C03DB02 CARDIOVASCULAR SYSTEM
DIURETICS
POTASSIUM-SPARING AGENTS
Other potassium-sparing agents
FDA PE N0000008859 Decreased Renal K+ Excretion
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175418 Potassium-sparing Diuretic
MeSH PA D004232 Diuretics
MeSH PA D062686 Epithelial Sodium Channel Blockers
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D045283 Natriuretic Agents
MeSH PA D026941 Sodium Channel Blockers
CHEBI has role CHEBI:35498 diuretics
CHEBI has role CHEBI:38633 sodium channel blockers

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Edema indication 267038008
Peripheral Edema due to Chronic Heart Failure indication
Pulmonary Edema due to Chronic Heart Failure indication
Hypokalemia off-label use 43339004
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Acidosis contraindication 51387008
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Megaloblastic anemia due to folate deficiency contraindication 85649008 DOID:14026
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Azotemia contraindication 445009001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.22 Basic
pKa2 5.5 Basic
pKa3 2.21 Basic
pKa4 0.54 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Amiloride-sensitive sodium channel, ENaC Ion channel BLOCKER IC50 5.30 IUPHAR CHEMBL
Cytochrome P450 2D6 Enzyme IC50 5 DRUG MATRIX
Caspase-1 Enzyme IC50 5.44 DRUG MATRIX
Cathepsin G Enzyme IC50 5.13 DRUG MATRIX
Solute carrier family 12 member 1 Transporter WOMBAT-PK
Pteridine reductase 1 Enzyme Ki 5.47 CHEMBL

External reference:

IDSource
4017902 VUID
N0000146253 NUI
D00386 KEGG_DRUG
4017902 VANDF
C0040869 UMLSCUI
CHEBI:9671 CHEBI
DX2 PDB_CHEM_ID
CHEMBL585 ChEMBL_ID
D014223 MESH_DESCRIPTOR_UI
5546 PUBCHEM_CID
1266 INN_ID
DB00384 DRUGBANK_ID
WS821Z52LQ UNII
4329 IUPHAR_LIGAND_ID
10763 RXNORM
5617 MMSL
80875 MMSL
d00396 MMSL
002315 NDDF
12512008 SNOMEDCT_US
387053007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
DYAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 0007-3650 CAPSULE 37.50 mg ORAL NDA 24 sections
MAXZIDE HUMAN PRESCRIPTION DRUG LABEL 2 0378-0460 TABLET 75 mg ORAL NDA 20 sections
MAXZIDE-25 HUMAN PRESCRIPTION DRUG LABEL 2 0378-0464 TABLET 37.50 mg ORAL NDA 20 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-1352 TABLET 37.50 mg ORAL NDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-1355 TABLET 75 mg ORAL NDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-2537 CAPSULE 37.50 mg ORAL ANDA 21 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0527-1632 CAPSULE 37.50 mg ORAL ANDA 20 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0591-0348 TABLET 75 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0591-0424 TABLET 37.50 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0615-1333 CAPSULE 37.50 mg ORAL ANDA 23 sections
Triamterene hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0615-3583 TABLET 37.50 mg ORAL ANDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0781-2074 CAPSULE 37.50 mg ORAL ANDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0781-2715 CAPSULE 50 mg ORAL ANDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10135-581 CAPSULE 37.50 mg ORAL ANDA 20 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10544-049 TABLET 37.50 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10544-076 TABLET 37.50 mg ORAL NDA 22 sections
Triamterene hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10544-080 TABLET 75 mg ORAL ANDA 23 sections
Triamterene hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10544-536 TABLET 37.50 mg ORAL ANDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10544-537 TABLET 75 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 16590-338 TABLET 37.50 mg ORAL ANDA 19 sections
Triamterene hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 21695-496 TABLET 37.50 mg ORAL ANDA 21 sections
Triamterene hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 21695-497 TABLET 75 mg ORAL ANDA 21 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 21695-839 CAPSULE 37.50 mg ORAL ANDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 33261-365 TABLET 75 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 33261-952 TABLET 37.50 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 35356-974 CAPSULE 37.50 mg ORAL ANDA 24 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 42291-841 CAPSULE 37.50 mg ORAL ANDA 20 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 42291-842 TABLET 37.50 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 43063-424 TABLET 37.50 mg ORAL NDA 22 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 45865-402 CAPSULE 37.50 mg ORAL ANDA 24 sections